A Voice for health equity

A Voice for health equity: Organon and J&J leaders champion the Voice to Parliament as a catalyst for change

Health Industry Hub May 17, 2023

Human Resources: In a thought-provoking interview with Health Industry Hub, industry leaders from the pharma and medtech sectors shed light on the significance of the Voice to Parliament in closing the gap in health equity for Aboriginal and Torres Strait Islander peoples.

With the upcoming referendum on the Voice to Parliament, Meshlin Khouri, Associate Director of Policy and Communications at Organon and Deborah Guion, Head of Global Community Impact at Johnson & Johnson expressed their organisations’ commitment to educating and raising awareness among their employees about the referendum and its potential implications. They recognised the historic nature of this moment and acknowledged the Voice to Parliament as a critical step towards reconciliation and creating a more inclusive nation.

In addressing some of the misconceptions and myths surrounding the Voice to Parliament, Deb and Meshlin highlighted the importance of engaging in open and respectful dialogue with individuals who may hold different perspectives. They emphasised the need for active listening and understanding to address concerns and dispel myths surrounding the referendum.

Meshlin stressed the importance of addressing existing healthcare inequities, particularly for women, and how the Uluru statement from the Heart aligns with Organon’s commitment to inclusivity and addressing disparities.

Deb emphasised that as corporate citizens, Johnson & Johnson has a responsibility to equip their workforce with the necessary knowledge to make informed choices. Understanding the history, significance, and potential impact of the Voice, will contribute to a more equitable and inclusive healthcare system.

As the conversation drew to a close, both health leaders highlighted the significance of this moment in the nation’s history and the need for active participation and informed choices from all.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.

News & Trends - MedTech & Diagnostics

Aussie medtech forges ahead, making inroads with new technology

Aussie medtech forges ahead, making inroads with new technology

Health Industry Hub | February 23, 2024 |

MedTech & Diagnostics News: Adelaide-based medical technology firm, LBT Innovations has successfully delivered its cutting-edge Automated Plate Assessment System (APAS) […]

More


News & Trends - Pharmaceuticals

Is the imposed PBS funding cap driving the migraine medicines shortage?

Is the imposed PBS funding cap driving the migraine medicines shortage?

Health Industry Hub | February 23, 2024 |

Pharma News: Australia finds itself grappling with an unparalleled shortage of migraine prevention medicines, leaving a significant impact on the […]

More


News & Trends - Pharmaceuticals

MSAC rejects Janssen's CAR T therapy despite clinical superiority, citing need for 'substantial price reduction'

MSAC rejects Janssen’s CAR T therapy despite clinical superiority, citing need for ‘substantial price reduction’

Health Industry Hub | February 23, 2024 |

Pharma News: The Medical Services Advisory Committee (MSAC) has deferred its decision on whether Janssen’s CAR T-cell therapy Carvykti (cilta-cel) […]

More


News & Trends - Pharmaceuticals

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Health Industry Hub | February 23, 2024 |

Pharma News: The Therapeutic Goods Administration (TGA) has granted approval for the first endometriosis treatment in 13 years. Gedeon Richter […]

More


This content is copyright protected. Please subscribe to gain access.